242 related articles for article (PubMed ID: 10421649)
1. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.
Lee SH; Shin MS; Lee HS; Bae JH; Lee HK; Kim HS; Kim SY; Jang JJ; Joo M; Kang YK; Park WS; Park JY; Oh RR; Han SY; Lee JH; Kim SH; Lee JY; Yoo NJ
Hum Pathol; 2001 Mar; 32(3):250-6. PubMed ID: 11274632
[TBL] [Abstract][Full Text] [Related]
3. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma.
Nagao M; Nakajima Y; Kanehiro H; Hisanaga M; Aomatsu Y; Ko S; Tatekawa Y; Ikeda N; Kanokogi H; Urizono Y; Kobayashi T; Shibaji T; Kanamura T; Ogawa S; Nakano H
Hepatology; 2000 Sep; 32(3):491-500. PubMed ID: 10960440
[TBL] [Abstract][Full Text] [Related]
4. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
5. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of death-associated protein-kinase expression in hepatocellular carcinomas.
Matsumoto H; Nagao M; Ogawa S; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Fujii H; Koyama F; Mukogawa T; Nakajima Y
Anticancer Res; 2003; 23(2B):1333-41. PubMed ID: 12820391
[TBL] [Abstract][Full Text] [Related]
10. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
12. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
13. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
[TBL] [Abstract][Full Text] [Related]
14. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
Lee SH; Shin MS; Lee JY; Park WS; Kim SY; Jang JJ; Dong SM; Na EY; Kim CS; Kim SH; Yoo NJ
J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
[TBL] [Abstract][Full Text] [Related]
15. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
16. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
[TBL] [Abstract][Full Text] [Related]
17. FasL:Fas ratio--a prognostic factor in breast carcinomas.
Reimer T; Herrnring C; Koczan D; Richter D; Gerber B; Kabelitz D; Friese K; Thiesen HJ
Cancer Res; 2000 Feb; 60(4):822-8. PubMed ID: 10706087
[TBL] [Abstract][Full Text] [Related]
18. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.
Bortolami M; Kotsafti A; Cardin R; Farinati F
J Viral Hepat; 2008 Jul; 15(7):515-22. PubMed ID: 18331250
[TBL] [Abstract][Full Text] [Related]
19. Fas/Fas ligand system and apoptosis induction in testicular carcinoma.
Schmelz HU; Abend M; Kraft K; Hauck EW; Weidner W; Van Beuningen D; Sparwasser C
Cancer; 2002 Jul; 95(1):73-81. PubMed ID: 12115319
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
